• Direct Mouse Genotyping Kit Plus: Streamlining Mouse Genetic

  2026-05-15

  Leverage the Direct Mouse Genotyping Kit Plus for rapid, purification-free mouse genotyping workflows. This kit empowers robust transgene detection, gene knockout validation, and high-throughput colony screening with exceptional ease and reliability.

• Amitriptyline HCl: Technical Guide for Experimental Use

  2026-05-14

  Amitriptyline HCl (SKU B2231) provides a well-characterized tool for researchers investigating neurotransmitter receptor modulation in neuropharmacology workflows, particularly where selectivity for serotonin, norepinephrine, 5-HT4, 5-HT2, and sigma-1 receptors is required. This compound is not suitable for workflows needing long-term solution stability or where mechanistic specificity outside its documented receptor profile is essential.

• THZ1: Covalent CDK7 Inhibitor for Advanced T-ALL Research

  2026-05-14

  THZ1 offers a unique, irreversible mechanism targeting CDK7, enabling researchers to overcome resistance in transcription regulation assays—especially for T-ALL models. This guide details practical workflows, troubleshooting insights, and the latest evidence on mutation-driven resistance, setting THZ1 apart as a critical tool in modern cancer biology.

• CA-074 Me: Strategic Inhibition of Cathepsin B in Necroptosi

  2026-05-13

  Explore the mechanistic, experimental, and translational dimensions of CA-074 Me—a potent, cell-permeable cathepsin B inhibitor—in unraveling necroptosis, apoptosis, and inflammation. This article bridges foundational insights with actionable strategies for translational researchers, incorporating recent advances and practical guidance to maximize the impact of lysosomal enzyme inhibition in disease models.

• RSL3 Glutathione Peroxidase 4 Inhibitor: Protocols & Tumor R

  2026-05-13

  The (1S,3R)-RSL3 glutathione peroxidase 4 inhibitor empowers researchers to induce ferroptosis with high specificity in RAS-driven tumor models. This article delivers actionable protocol enhancements, troubleshooting strategies, and translational guidance for maximizing RSL3's impact in cancer biology and oxidative stress modulation.

• Nanocrystal Formulation Enhances Ziprasidone HCl Cell Permea

  2026-05-12

  Karaküçük et al. investigated nanocrystal formulations of ziprasidone hydrochloride monohydrate (ZHM) and found a 2.3-fold increase in Caco-2 cell permeability compared to coarse powder, with no cytotoxicity. These findings directly address bioavailability limitations of ZHM, informing future development of antipsychotic and translational research workflows.

• Quercetin Inhibits Ferroptosis to Mitigate Liver Injury in W

  2026-05-12

  This study systematically demonstrates that quercetin alleviates liver injury in Wilson's disease by directly inhibiting the ACSL4/LPCAT3/ALOX15-mediated ferroptosis pathway. These findings provide mechanistic evidence for ferroptosis-targeted therapies and position quercetin as a multi-target modulator for hepatic protection in metal overload conditions.

• Methyl-β-cyclodextrin: Technical Guidance for Membrane Studi

  2026-05-11

  Methyl-β-cyclodextrin (SKU C6939) is a high-purity reagent for extracting cholesterol and select lipids from cellular membranes, enabling researchers to control membrane fluidity and study lipid raft dynamics. It is intended for laboratory research use only and should not be used in diagnostic or therapeutic applications.

• T7 RNA Polymerase: Mechanism, Evidence, and Workflow Integra

  2026-05-11

  T7 RNA Polymerase is a recombinant enzyme expressed in E. coli, highly specific for T7 promoter-driven in vitro transcription. Its robust activity underpins RNA synthesis for research and RNA vaccine production. We summarize its molecular mechanism, evidence base, and best-practice usage parameters.

• SCUBE3 Antibody Targeting Disrupts Oncogenic Signaling in Ca

  2026-05-10

  This study identifies secretory SCUBE3 as a pivotal driver of tumor growth, therapy resistance, and immune evasion in multiple cancer types. Antibody-mediated targeting of SCUBE3 disrupts oncogenic signaling via EGFR and related pathways, restores antitumor immunity, and demonstrates broad preclinical efficacy, highlighting SCUBE3 as a promising therapeutic target.

• Aβ42 Peptide: Mechanistic Insights for Translational AD Rese

  2026-05-09

  This article delivers a thought-leadership perspective on Amyloid β-Peptide (1-42) (Aβ42) as a driver of Alzheimer’s disease mechanisms, bridging molecular insights with strategic guidance for translational researchers. It explores Aβ42’s dual roles in neurotoxicity and microglial activation, integrates recent reference findings, and provides actionable protocol parameters rooted in the latest evidence. Distinct from workflow guides, this piece frames the competitive landscape and articulates the translational impact of leveraging rigorously characterized peptides such as APExBIO’s Amyloid β-Peptide (1-42) (human).

• PFOS-Induced Ferroptosis and ER Stress in HK-2 Cells: Mechan

  2026-05-08

  This study rigorously demonstrates that perfluorooctane sulfonate (PFOS) induces injury in human renal proximal tubular (HK-2) cells through activation of ferroptosis and endoplasmic reticulum (ER) stress pathways. The findings provide mechanistic insight into PFOS nephrotoxicity, with practical implications for modeling ER stress in vitro and guiding the use of chemical chaperones for pathway dissection.

• Prednisolone in Glucocorticoid Signaling: Mechanistic Insigh

  2026-05-08

  Explore how Prednisolone, a synthetic glucocorticoid, advances glucocorticoid signaling and inflammation modulation research. This article uniquely connects small-molecule assay design with new protein degradation strategies.

• circHIF1A/miR-486-5p/GRHL2 Axis Drives LUAD Progression via

  2026-05-07

  This study uncovers how circHIF1A, acting through the miR-486-5p/GRHL2 axis, promotes macrophage M2 polarization and accelerates lung adenocarcinoma (LUAD) progression. These findings define a novel regulatory circuit within the tumor microenvironment, highlighting potential diagnostic markers and therapeutic targets for LUAD.

• Q-VD(OMe)-OPh: Optimizing Caspase Inhibition in Apoptosis As

  2026-05-07

  Q-VD(OMe)-OPh redefines caspase inhibition, enabling robust, non-toxic modulation of apoptosis in cell-based and in vivo models. This guide translates breakthrough experimental findings into actionable workflows and troubleshooting strategies for apoptosis, neuroprotection, and cancer resistance research.

15655 records 2/1044 page Previous Next 12345 下5页 Last page